AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28320187 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex
Number of subjects: 13
Study 28320187 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 13
Study 26468007 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus cisplatin (CC)
Number of subjects: 94
Study 26468007 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus paclitaxel (CP)
Number of subjects: 94
Study 23278145 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-headed toothbrush
Number of subjects: 43
Study 23278145 — intervention group
Group type: COMPARATOR
Intervention: Single-headed toothbrush
Number of subjects: 43
Study 21854199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil aromatherapy (oxygen with a face mask coated with lavender oil for 5 minutes)
Number of subjects: 30
Study 21854199 — intervention group
Group type: COMPARATOR
Intervention: Control (oxygen through a face mask with no lavender oil for 5 minutes)
Number of subjects: 30
Study 19698089 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral continuous theta burst stimulation (cTBS) applied to the secondary auditory cortex
Number of subjects: 48
Study 19698089 — intervention group
Group type: EXPERIMENTAL
Intervention: bilateral continuous theta burst stimulation (cTBS) applied to the temporoparietal association cortex
Number of subjects: 48
Study 19698089 — intervention group
Group type: COMPARATOR
Intervention: sham condition (lower occiput)
Number of subjects: 48
Study 16426274 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic daily headache (CDH)
Number of subjects: 308
Study 16426274 — intervention group
Group type: COMPARATOR
Intervention: Episodic headache (EH)
Number of subjects: 308
Study 16426274 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug addicts (DA)
Number of subjects: 308
Study 15533865 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasimibe 50 mg QD
Number of subjects: 100
Study 15533865 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasimibe 250 mg QD
Number of subjects: 100
Study 15533865 — intervention group
Group type: EXPERIMENTAL
Intervention: Avasimibe 750 mg QD
Number of subjects: 100
Study 15533865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11375853 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 45
Study 11375853 — intervention group
Group type: COMPARATOR
Intervention: Combination of GA and intraoperative thoracic epidural analgesia (TEA)
Number of subjects: 45
Study 11375853 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal approach (intraoperative GA and TEA, postoperative patient‐controlled TEA, early oral nutrition, enforced mobilization)
Number of subjects: 45
Study 9466279 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg p.o. twice a day followed by a 2-month taper)
Number of subjects: 64
Study 9466279 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive clinical scoring system
Number of subjects: 64
Study 8543105 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine obstetric ultrasound
Number of subjects: 0
Study 2332565 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide
Number of subjects: 10
Study 2332565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 467943 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfasalazine
Number of subjects: 569
Study 467943 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisone or azathioprine
Number of subjects: 569
Study 467943 — intervention group
Group type: EXPERIMENTAL
Intervention: ileocolitis
Number of subjects: 569
Study 467943 — intervention group
Group type: COMPARATOR
Intervention: small bowel disease
Number of subjects: 569
Study 467943 — intervention group
Group type: EXPERIMENTAL
Intervention: colitis or ileocolitis
Number of subjects: 569
Study 467943 — intervention group
Group type: EXPERIMENTAL
Intervention: perianal disease
Number of subjects: 569
Study 31091717 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-core foods
Number of subjects: 36
Study 31091717 — intervention group
Group type: EXPERIMENTAL
Intervention: Core foods
Number of subjects: 36
Study 31091717 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-core food snacking
Number of subjects: 36
Study 31091717 — intervention group
Group type: EXPERIMENTAL
Intervention: Core food snacking
Number of subjects: 36
Study 31091717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals
Number of subjects: 36
Study 31091717 — intervention group
Group type: EXPERIMENTAL
Intervention: Purchased products
Number of subjects: 36
Study 27203271 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart cluster (chest pain/discomfort and palpitations/fluttering)
Number of subjects: 335
Study 27203271 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal cluster (nausea and diaphoresis)
Number of subjects: 335
Study 27203271 — intervention group
Group type: EXPERIMENTAL
Intervention: Tired cluster (fatigue/lethargy, weakness, syncope/dizziness, and dyspnea/breathlessness)
Number of subjects: 335
Study 25855155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceralifimod 0.10 mg
Number of subjects: 24
Study 25855155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 24
Study 25855155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceralifimod (0.05 mg)
Number of subjects: 24
Study 25855155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (0.5 mg)
Number of subjects: 24
Study 25855155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceralifimod
Number of subjects: 24
Study 25855155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24965190 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 80
Study 24965190 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 80
Study 22776351 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely obese children
Number of subjects: 100
Study 20389096 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified hMG (Menopur)
Number of subjects: 5
Study 20389096 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (Gonal‐F)
Number of subjects: 5
Study 17699990 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 17699990 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 16159816 — intervention group
Group type: EXPERIMENTAL
Intervention: SICTRA with MV surgery (group A)
Number of subjects: 70
Study 16159816 — intervention group
Group type: COMPARATOR
Intervention: MV surgery alone (group B)
Number of subjects: 70
Study 12105160 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) 10 mg/24 hours
Number of subjects: 0
Study 12105160 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) with ascorbate (2.4 g/24 hours)
Number of subjects: 0
Study 10022633 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term NSAID therapy (Group I)
Number of subjects: 95
Study 10022633 — intervention group
Group type: EXPERIMENTAL
Intervention: No NSAID therapy (Group II)
Number of subjects: 95
Study 10022633 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (Group III)
Number of subjects: 95
Study 8815569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) certoparin (3,000 IU) combined with dihydroergotamine (DHE) (0.5 mg) subcutaneously once daily
Number of subjects: 305
Study 8815569 — intervention group
Group type: COMPARATOR
Intervention: Adjusted-dose unfractionated heparin (UFH) subcutaneously every 8 hours
Number of subjects: 305
Study 1381636 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 660
Study 1381636 — intervention group
Group type: COMPARATOR
Intervention: Cephamandole
Number of subjects: 660
Study 6339343 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone and 500 mg Na p.d
Number of subjects: 328
Study 6339343 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone + furosemide or Moduretic and 500 mg Na p.d
Number of subjects: 328
Study 6339343 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone + Furosemide or Moduretic and unrestricted sodium diet
Number of subjects: 328
Study 6339343 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ascites reinfusion and 500 mg Na p.d
Number of subjects: 328
Study 6339343 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified ascites reinfusion and 500 mg Na p.d
Number of subjects: 328
Study 6339343 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow ascites drainage and 500 mg Na p.d
Number of subjects: 328
Study 31450257 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Focused Group Counseling (SFGC) for 5 sessions of 75 minutes each
Number of subjects: 40
Study 31450257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 31450257 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Focused Group Counseling (SFGC)
Number of subjects: 40
Study 28329121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex/HE
Number of subjects: 117
Study 28329121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex/Diet
Number of subjects: 117
Study 28329121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex/VLCD
Number of subjects: 117
Study 26218729 — intervention group
Group type: EXPERIMENTAL
Intervention: rimabotulinumtoxinB (1,500 U)
Number of subjects: 24
Study 26218729 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxinA (50 U)
Number of subjects: 24
Study 23704830 — intervention group
Group type: EXPERIMENTAL
Intervention: Danzhijiangtang capsule (DJC)
Number of subjects: 62
Study 23704830 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine western medicine)
Number of subjects: 62
Study 21422407 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4325
Study 21422407 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4325
Study 21422407 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Exemestane and Tamoxifen)
Number of subjects: 4325
Study 21422407 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative analysis of ER and PgR expression
Number of subjects: 4325
Study 19137351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 672
Study 19137351 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hip protectors)
Number of subjects: 672
Study 17199134 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 80 mg + LHRH-A
Number of subjects: 205
Study 17199134 — intervention group
Group type: COMPARATOR
Intervention: LHRH-A
Number of subjects: 205
Study 15003438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 g liquid paraffin per day)
Number of subjects: 11
Study 15003438 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) (2 g per day)
Number of subjects: 11
Study 15003438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15003438 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA
Number of subjects: 11
Study 11307178 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of antioxidants
Number of subjects: 46
Study 11307178 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 46
Study 1307880 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-wavelength continuous SvO2 catheter
Number of subjects: 60
Study 1307880 — intervention group
Group type: COMPARATOR
Intervention: Two-wavelength continuous SvO2 catheter
Number of subjects: 60
Study 3986067 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural local anaesthetics (0.5% bupivacaine)
Number of subjects: 3
Study 3986067 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural morphine
Number of subjects: 3
Study 3986067 — intervention group
Group type: COMPARATOR
Intervention: Control group (morphine i.v.)
Number of subjects: 3
Study 29427365 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative self-focused thought (negative-SFT)
Number of subjects: 79
Study 29427365 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression group
Number of subjects: 79
Study 27090364 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus (D.pt) extract
Number of subjects: 61
Study 27090364 — intervention group
Group type: COMPARATOR
Intervention: Control group (drugs only)
Number of subjects: 61
Study 24173029 — intervention group
Group type: EXPERIMENTAL
Intervention: HiP-AS (with AS03 adjuvant)
Number of subjects: 40
Study 24173029 — intervention group
Group type: EXPERIMENTAL
Intervention: HiP (without AS03 adjuvant)
Number of subjects: 40
Study 24173029 — intervention group
Group type: COMPARATOR
Intervention: Engerix B (control)
Number of subjects: 40
Study 24173029 — intervention group
Group type: EXPERIMENTAL
Intervention: HiP-AS
Number of subjects: 40
Study 24173029 — intervention group
Group type: EXPERIMENTAL
Intervention: HiP
Number of subjects: 40
Study 24173029 — intervention group
Group type: EXPERIMENTAL
Intervention: HiP-AS and HiP
Number of subjects: 40
Study 22933427 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (E+P)
Number of subjects: 2535
Study 22933427 — intervention group
Group type: COMPARATOR
Intervention: Estrogen alone (E‐alone)
Number of subjects: 2535
Study 22933427 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (E+P or E‐alone)
Number of subjects: 2535
Study 22933427 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of 2‐OHE1 and the 2:16 ratio
Number of subjects: 2535
Study 22933427 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of 16α‐OHE1
Number of subjects: 2535
Study 20530393 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated intervention
Number of subjects: 36
Study 20530393 — intervention group
Group type: COMPARATOR
Intervention: Self-directed intervention
Number of subjects: 36
Study 19020132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S)
Number of subjects: 60
Study 19020132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and dexmedetomidine (group SD)
Number of subjects: 60
Study 19020132 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 60
Study 19020132 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and dexmedetomidine (group PD)
Number of subjects: 60
Study 16872308 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol and ascorbic acid (vitamins)
Number of subjects: 32
Study 16872308 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamins)
Number of subjects: 32
Study 14654605 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg of elemental zinc as zinc sulfate in vitamin B complex‐based syrup, 1 mL daily)
Number of subjects: 100
Study 14654605 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL of vitamin‐based syrup)
Number of subjects: 100
Study 14654605 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 100
Study 11304647 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intramuscular haloperidol
Number of subjects: 21
Study 11304647 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 21
Study 8985531 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 259
Study 8985531 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 259
Study 8985531 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD
Number of subjects: 259
Study 1738183 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of isotretinoin daily
Number of subjects: 981
Study 1738183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 981
Study 3547351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 227
Study 3547351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 227
Study 3547351 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 650 mg
Number of subjects: 227
Study 3547351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 100 mg
Number of subjects: 227
Study 3547351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 30025537 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 45
Study 30025537 — intervention group
Group type: COMPARATOR
Intervention: Doctors
Number of subjects: 45
Study 30025537 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 45
Study 27431041 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 40
Study 27431041 — intervention group
Group type: COMPARATOR
Intervention: Control condition (educational intervention)
Number of subjects: 40
Study 24803366 — intervention group
Group type: EXPERIMENTAL
Intervention: VR‐JIT (Virtual Reality Job Interview Training)
Number of subjects: 26
Study 24803366 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 26
Study 23253481 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Approach to Management of Maternal Asthma (MAMMA©)
Number of subjects: 0
Study 23253481 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21572016 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous incremental supine cycling exercise
Number of subjects: 9
Study 21572016 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous incremental supine cycling exercise
Number of subjects: 9
Study 21572016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise protocols
Number of subjects: 9
Study 20031720 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-molecule glycoprotein IIb/IIIa inhibitors (tirofiban or eptifibatide)
Number of subjects: 2138
Study 20031720 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 2138
Study 16543129 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurons in the medial temporal lobe (MTL) during a learning task
Number of subjects: 0
Study 12771472 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C iontophoresis
Number of subjects: 29
Study 12771472 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 29
Study 10874265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 19185
Study 10874265 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 19185
Study 9398932 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0
Study 9398932 — intervention group
Group type: COMPARATOR
Intervention: L-alpha-acetylmethadol (LAAM)
Number of subjects: 0
Study 1287107 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine, 50 mg by mouth
Number of subjects: 62
Study 1287107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 1287107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine, 0.033 mg/kg
Number of subjects: 62
Study 1287107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine, 0.10 mg/kg
Number of subjects: 62
Study 3907989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (400 mg twice daily)
Number of subjects: 30
Study 3907989 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg twice daily)
Number of subjects: 30
Study 30955403 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS to left primary motor cortex (Group M1, n=10)
Number of subjects: 30
Study 30955403 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS to left dorsolateral prefrontal cortex (Group DLPFC, n=10)
Number of subjects: 30
Study 30955403 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (Group sham, n=10)
Number of subjects: 30
Study 29936726 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS program family-based intervention (6 sessions covering family involvement, optimism, cancer coping, uncertainty reduction, symptom management)
Number of subjects: 60
Study 29936726 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 27464793 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (group A)
Number of subjects: 60
Study 27464793 — intervention group
Group type: COMPARATOR
Intervention: Passive physical therapy (group B)
Number of subjects: 60
Study 25056569 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum micronutrient treatment
Number of subjects: 0
Study 25056569 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 22341632 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoselective vaporization of the prostate (PVP) with GreenLight HPS 120-W laser
Number of subjects: 139
Study 22341632 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (TURP)
Number of subjects: 139
Study 20657097 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education (DHE) conducted every three weeks
Number of subjects: 415
Study 20657097 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental health education (DHE) conducted every six weeks
Number of subjects: 415
Study 20657097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 415
Study 18572041 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC diet with 0.5 cups of soy nuts (25 g soy protein and 101 mg aglycone isoflavones)
Number of subjects: 60
Study 18572041 — intervention group
Group type: COMPARATOR
Intervention: TLC diet alone
Number of subjects: 60
Study 18572041 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC diet with soy nuts
Number of subjects: 60
Study 16093734 — intervention group
Group type: EXPERIMENTAL
Intervention: High walnut diet (20 energy%)
Number of subjects: 68
Study 16093734 — intervention group
Group type: EXPERIMENTAL
Intervention: High cashew diet (20 energy%)
Number of subjects: 68
Study 16093734 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 68
Study 11879257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg)
Number of subjects: 34
Study 11879257 — intervention group
Group type: COMPARATOR
Intervention: Antacid (30-ml dose of magnesium hydroxide/aluminium hydroxide)
Number of subjects: 34